NFL Biosciences SAS
Research NFL Biosciences SAS (ALNFL) on Bullrun: market cap EUR 11.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALNFL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 11.23M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 3.32M
Valuation Snapshot
latest market cap is EUR 11.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 3.32M | n/a | n/a | n/a | EUR 2.00M | EUR 582.59K | EUR 306.14K |
| FY2024 | EUR 0 | -EUR 2.08M | n/a | n/a | n/a | EUR 1.91M | EUR 40.98K | EUR 976.43K |
| FY2023 | EUR 0 | -EUR 3.75M | n/a | n/a | -0.46 | EUR 2.34M | EUR 62.17K | EUR 349.95K |
| FY2022 | EUR 0 | -EUR 2.44M | n/a | n/a | -0.47 | EUR 1.05M | EUR 83.26K | EUR 844.00K |
| FY2021 | n/a | n/a | n/a | n/a | -0.19 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 11.23M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NFL Biosciences SAS's market cap?
NFL Biosciences SAS's market capitalization is EUR 11.23M.
What does NFL Biosciences SAS do?
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation.